high response rate when using a bispecific antibody to treat R/R multiple myeloma.

Published Date: 12 Apr 2024

71 percent ORR that increased over time, along with a good safety record when using linvoseltamab.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Study indicates that exercise can help colon cancer survivors live as long as matched individuals

2.

Personalized Breast Cancer Treatment; Insights Into HPV in Men; Exercise and Cancer

3.

Significant differences in breast cancer care still exist, but surgeons can change.

4.

Immune cell homing hydrogel-based platform captures dendritic cells to process mRNA from cancer vaccines

5.

'Cell-in-cell' mechanism explains how blood cancer uses bone marrow to evade treatment


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot